Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

27.32
+1.254.79%
Post-market: 27.30-0.0201-0.07%19:39 EST
Volume:1.36M
Turnover:37.17M
Market Cap:3.35B
PE:-77.91
High:27.50
Open:26.50
Low:26.41
Close:26.07
52wk High:31.77
52wk Low:11.13
Shares:122.49M
Float Shares:88.24M
Volume Ratio:0.95
T/O Rate:1.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3506
EPS(LYR):-1.1578
ROE:-28.17%
ROA:-5.91%
PB:21.17
PE(LYR):-23.60

Loading ...

Arcutis Biotherapeutics Grants 94,000 Restricted Stock Units to New Employees

Reuters
·
Yesterday

Press Release: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
Yesterday

Director Howard G. Welgus Reports Sale of Arcutis Biotherapeutics Common Shares

Reuters
·
Feb 05

Arcutis Biotherapeutics Reports Positive Phase 2 Results for ZORYVE Cream in Infants with Atopic Dermatitis

Reuters
·
Feb 02

Arcutis Biotherapeutics Inc - Plans to Submit Snda for Zoryve Cream in Q2 2026

THOMSON REUTERS
·
Feb 02

Arcutis Biotherapeutics Inc: Investigational Zoryve Cream 0.05% Was Well Tolerated

THOMSON REUTERS
·
Feb 02

Arcutis Announces Positive Topline Results for Integument-Infant Phase 2 Trial of Zoryve® (Roflumilast) Cream 0.05% in Infants With Mild to Moderate Atopic Dermatitis

THOMSON REUTERS
·
Feb 02

Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (ARQT) and Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF)

TIPRANKS
·
Jan 27

Arcutis Biotherapeutics Is Maintained at Buy by Needham

Dow Jones
·
Jan 27

Arcutis Terminates Promotion Agreement for Zoryve With Kowa Pharmaceuticals America

MT Newswires Live
·
Jan 26

Arcutis Biotherapeutics announces termination of promotion agreement with Kowa

TIPRANKS
·
Jan 26

Arcutis Biotherapeutics Inc - Kowa to Cease All Sales and Promotions of Zoryve

THOMSON REUTERS
·
Jan 26

Arcutis Biotherapeutics Inc - to Assume Sales and Promotion of Zoryve

THOMSON REUTERS
·
Jan 26

Is It Time To Reassess Arcutis Biotherapeutics (ARQT) After A 96% One Year Rally?

Simply Wall St.
·
Jan 24

Arcutis announces results of survey on inflammatory skin conditions

TIPRANKS
·
Jan 21

BTIG Reaffirms Their Buy Rating on Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
Jan 15

Mizuho Securities Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)

TIPRANKS
·
Jan 13

BRIEF-Arcutis Highlights 2026 Strategic Priorities And Anticipated Milestones

Reuters
·
Jan 12

Arcutis Biotherapeutics Projects 2026 ZORYVE Sales of $455-$470 Million

Reuters
·
Jan 12

Arcutis Biotherapeutics Inc - Topline Results From Integument-Infant Phase 2 Study Expected Q1 2026

THOMSON REUTERS
·
Jan 12